Azafaros

Focus: Azafaros is a Netherlands-based biotechnology company founded in 2018 focused on small molecule therapeutics. The company operates at an early-to-mid stage with a concentrated pipeline in rare genetic diseases.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Azafaros

AI assessmentNot Hiring

No open roles listed right now. Follow Azafaros to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO)

GM1 Gangliosidosis

N/A

Clinical Trials (1)

NCT05109793GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO)

N/A

Help build intelligence for Azafaros

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead role opportunity on Phase 3 program (Nizubaglustat) in rare disease with 5 active trials providing visibility into near-term clinical data
Small molecule focus in rare genetic disease (Niemann-Pick Type C) offers deep scientific specialization and meaningful patient impact
Early-stage company (founded 2018) provides flat organization structure and direct influence on clinical and commercial strategy

Watch Out For

Zero active job postings indicate either fully staffed stage or potential hiring freeze, limiting entry opportunities
Pre-revenue biotech status with undisclosed funding creates unknown cash runway and financial stability risks

Generated by Claude from Azafaros's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AZ-3102

GM2 Gangliosidosis

Phase 2

Clinical Trials (1)

NCT05758922Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients with GM2 Gangliosidosis or Niemann-Pick Type C Disease

Phase 2

Nizubaglustat

Niemann-Pick Type C Disease

Phase 3

Clinical Trials (4)

NCT07082543A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

Phase 3

NCT07054515A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

Phase 3

NCT07082725A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

Phase 3

+1 more

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2018

Portfolio: 6 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo